Foundayo's $98 million launch quarter

Eli Lilly reported $98 million in second-quarter 2026 revenue for Foundayo, the brand name for orforglipron, after launching the oral GLP-1 medicine in the United States during the quarter^[1]. That is a small opening next to Lilly's established injectable medicines, but the filing does not call the launch disappointing and gives no company forecast against which to judge the result. The defensible reading is narrower: Foundayo had its first $98 million sales quarter while tirzepatide products still generated most of Lilly's incretin revenue.

What Lilly actually reported

Lilly's earnings release lists Foundayo revenue of $98 million for both the quarter and the year to date, with no revenue in the comparison period. The table marks the year-over-year change as not meaningful because there was no 2025 base^[1]. Lilly also added Foundayo to its group of key products in the second quarter^[1]. Those details identify an early commercial launch. They do not establish whether sales beat or missed an internal target.

The same release puts total company revenue at $22.974 billion for the quarter, up 48% from $15.558 billion a year earlier. Mounjaro revenue was $9.943 billion and Zepbound revenue was $4.928 billion^[1]. Foundayo therefore started from a much smaller base than Lilly's injectable tirzepatide brands. That comparison describes scale, not clinical value and not the eventual size of the oral market.

Why the injectable comparison needs care

Mounjaro and Zepbound are both brands of tirzepatide. Lilly's quarterly filing says the two products accounted for 65% of company revenue during the first half of 2026^[2]. Readers can review the molecule and its evidence on our tirzepatide page. A new tablet entering a market led by those products will almost automatically look small in a first-quarter revenue comparison.

Several factors can shape launch-quarter sales without revealing long-term demand: the number of weeks a product was available, pharmacy stocking, insurance coverage, patient eligibility, and the timing of prescriptions. Lilly's two official quarterly documents do not separate those effects for Foundayo. They also do not disclose unit volume or an average realized price for the product. Revenue alone cannot show how many people began treatment or stayed on it.

What Foundayo is

Foundayo is Lilly's brand for orforglipron. The 10-Q identifies it as an oral GLP-1 receptor agonist and says the FDA approved it for obesity before the company launched it in the United States in the second quarter of 2026^[2]. A GLP-1 receptor agonist is a medicine that activates a receptor involved in appetite and blood-sugar regulation. Foundayo is not an oral version of tirzepatide, and it is not semaglutide. These are different active ingredients, even though they sit in the broader incretin field.

Lilly says it licensed worldwide development and commercialization rights to orforglipron from Chugai Pharmaceutical. Chugai receives tiered royalties on worldwide net sales ranging from the mid-single digits to the low teens^[2]. That licensing structure matters when reading sales because reported product revenue and the economics Lilly ultimately keeps are not identical.

What the quarter does and does not show

The quarter shows that Foundayo began contributing revenue, while Lilly's injectable franchise remained much larger. It does not show that tablets are replacing injections, that one route works better, or that Foundayo has failed to find demand. Those questions need prescription trends, coverage data, longer sales history, and clinical evidence rather than one line in a product-revenue table.

The official release also says US revenue rose 33% to $14.4 billion, with higher volume partly offset by lower realized prices. Outside the United States, revenue rose 80% to $8.6 billion, with Mounjaro driving the volume increase^[1]. Lilly did not provide a comparable geographic breakdown for Foundayo in the release. It would be an inference to assign the wider company's pricing or volume pattern to the pill.

What to watch next

Lilly's 10-Q says near-term financial performance will depend partly on demand and uptake in new channels and markets, including US Medicare for both Foundayo and Zepbound. It also points to the timing of possible additional orforglipron approvals^[2]. Future quarterly reports should make the launch easier to assess by adding more time, more markets, and a clearer trend. A single first-quarter figure cannot supply that context.

For clinical questions, sales are the wrong endpoint. Our semaglutide evidence page and tirzepatide evidence page separate trial findings from commercial performance. A medicine can sell quickly without being right for every patient, and a slow launch would not by itself disprove efficacy. Treatment choices belong with a qualified healthcare professional using the current label and the person's medical history.

Medical disclaimer: this article is for educational and journalistic purposes only and does not constitute medical advice. GLP-1 medicines are prescription products. Always consult a qualified healthcare professional before starting, switching, or stopping treatment. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.